Kinase Inhibitors that Increase the Sensitivity of Methicillin Resistant Staphylococcus aureus to β-Lactam

Jay Vornhagen1,2,3, Kellie Burnside4, Christopher Whidbey5,6,7

  • 1Department of Pediatric Infectious Diseases, University of Washington School of Medicine, Seattle, WA 98195, USA. jay.vornhagen@seattlechildrens.org.

Insights

Four novel kinase inhibitors enhance susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics. These compounds show promise for new MRSA infection therapies with low toxicity in preliminary studies.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Staphylococcus aureus is a leading cause of recurrent human infections.
  • Methicillin-resistant S. aureus (MRSA) poses a significant therapeutic challenge.
  • MRSA strains lacking serine/threonine kinase (Stk1/PknB) show increased sensitivity to beta-lactam antibiotics.

Purpose of the Study:

  • To identify kinase inhibitors that increase MRSA sensitivity to beta-lactam antibiotics.
  • To evaluate the in vivo toxicity of identified kinase inhibitors.

Main Methods:

  • Screening of 280 low-molecular-weight kinase inhibitors against wild-type MRSA.
  • Testing inhibitor efficacy in combination with sub-lethal beta-lactam concentrations.
  • Assessing compound toxicity in a murine model.

Main Results:

  • Identified four sulfonamide kinase inhibitors (ST085384, ST085404, ST085405, ST085399) that enhance WT MRSA sensitivity to beta-lactams.
  • Inhibitors lacked common toxic structural alerts.
  • No in vivo toxicity observed for ST085384 and ST085405 in mice.

Conclusions:

  • Kinase inhibitors can re-sensitize MRSA to beta-lactam antibiotics.
  • Specific sulfonamide compounds demonstrate potential as adjuncts for MRSA treatment.
  • Further investigation into these kinase inhibitors for MRSA therapeutic strategies is warranted.

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
33
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
99
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
58
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.4K
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
46
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These...
43